A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
Genesis Cancer and Blood Institute, Hot Springs, Arkansas Yale University School of Medicine, New Haven, Connecticut NYU Langone, New York, New York The Ohio State University, Gahanna, Ohio MD Anderson, Houston, Texas Inova Schar Cancer, Fairfax, Virginia Last updated February 2026